Therapeutic Fc-Fusion Proteins (ePub)

Steven M. Chamow, PhD is currently the principal at Chamow & Associates, Inc., a biopharmaceutical
consulting firm. He has developed protein therapeutics for 26 years and contributed to the development of three marketed products (Avastin, Natrecor, Vectibix). He began his career in process development at Genentech, Inc. and has served in management and executive roles at several other biotechnology companies. He is author or co-author of more than 45 scientific publications and patents and co-editor of a 1999 book entitled Antibody Fusion Proteins. Educated at the University of California and trained at the National Institutes of Health, he lives in San Mateo, CA with his wife.

Thomas Ryll, PhD currently serves as Senior Director of Cell Culture Development at Biogen Idec in Cambridge, MA. He has contributed to the development of several marketed products, including Rituxan, Raptiva, Vectibix, Eloctate and Alprolix. He began his career at Genentech, Inc. as scientist in process development. Since then, he served in various scientific and management roles with increasing responsibilities at Abgenix, Inc., Tanox Inc., and Biogen Idec, Inc. Educated at the Technical University of Braunschweig in Germany, he is author or co-author of more than 35 scientific publications and patents. He lives in Lexington, MA with his family.

Henry B. Lowman, PhD currently serves as Chief Scientific Officer at CytomX Therapeutics, Inc.
Dr. Lowman served a 20-year tenure at Genentech, Inc., where he focused on protein and antibody therapeutics. His career interests include structure-based protein design, structure-function analysis, and molecular diversity techniques. Dr. Lowman is an author on more than 60 scientific publications, inventor on more than 60 issued patents, and an editorial board member for the
antibody journal mAbs. Dr. Lowman earned his B.A. in chemistry at Johns Hopkins University and PhD in chemistry at Purdue University.

Deborah Farson is the principal at

Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.